Contract W81K0024F0177
Novartis Pharmaceuticals Corporation · Department Of Defense · September 19, 2024
Novartis Pharmaceuticals Corporation was awarded a federal contract by Department Of Defense (Department Of The Army) on September 19, 2024 for $23,000 of work in pharmaceutical preparation manufacturing. Performance is in Jbsa Ft Sam Houston, TX. This is a task or delivery order issued under parent IDIQ W81K0024D0004. The contract has been modified 1 time since the base award It uses firm fixed-price contract pricing. The most recent modification was on July 1, 2025. If all options are exercised, the contract could reach $3.39 million.
Contract details
- PIID
- W81K0024F0177
- Parent IDIQ
- W81K0024D0004
- Award type
- Delivery Order
- Pricing
- Fixed Price With Economic Price Adjustment
- Competition
- Not Competed
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Jbsa Ft Sam Houston, TX
- First action
- September 19, 2024
- Latest action
- July 1, 2025
Description
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
Modification timeline
-
July 1, 2025Mod P00002 · Funding Only Action$3.39M
-
September 19, 2024Base awardDELIVERY ORDER FOR PLUVICTO AND LUTATHERA$3.39M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $51 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $91 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $32 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $1.1K |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $22 |
| Cardinal Health, Inc. | Department Of Defense | December 31, 2025 | $23 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract W81K0024F0177?
Contract W81K0024F0177 is a federal contract awarded to Novartis Pharmaceuticals Corporation by Department Of Defense on September 19, 2024 for $23,000 of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 1 time since the base award.
Who won contract W81K0024F0177?
Novartis Pharmaceuticals Corporation won contract W81K0024F0177 from Department Of Defense.
How much is contract W81K0024F0177 worth?
Contract W81K0024F0177 has obligated $23,000 to date, with a total potential value of $3.39 million if all options are exercised.